Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- RaQualia Licenses 5-HT4 Partial Agonist to CJ CheilJedang in South Korea
August 8, 2011
- Fujifilm, DRL Announce Plans to Establish Generic Drugs JV in Japan
August 8, 2011
- Astellas Transfers Investigational Anti-arrhythmic Agent to Merck Subsidiary
August 8, 2011
- Revision Proposed to 70% Rule for Pricing of New Generics
August 8, 2011
- Teijin Pharma's Gout Agent Febuxostat Launched in South Korea
August 8, 2011
- Korosho Orders 10-Day Suspension of Operations for Kobayashi Medical
August 8, 2011
- M3 to Promote Clinical Study Support Business by Acquiring SMO
August 8, 2011
- Roche to File for mBC Treatment Pertuzumab in Japan in 2012
August 8, 2011
- Korosho to Publish JAMS's Opinions on Switch OTC Drug Candidates Sometime in August
August 8, 2011
- Chuikyo to Assess Impact of “Premium for Development of New Drugs”
August 8, 2011
- Millennium Submits sNDA for Velcade in US
August 8, 2011
- Axitinib to Be Used in 3rd-line Therapy for RCC: Kantar Health
August 8, 2011
- Revisions Proposed to Re-pricing Rule, Adjustment Based on Average Overseas Prices
August 8, 2011
- US FDA Issues Refusal to File Letter for Eisai's Perampanel
August 8, 2011
- “Dispensing Point”System Contributing to Higher Average Price per Prescription: GROWELL
August 8, 2011
- Proemend, Teribone Recommended for Approval
August 8, 2011
- Application for Zonegran Monotherapy for Epilepsy Accepted in Europe: Eisai
August 8, 2011
- JAS to Assess Risk Factors Based on Absolute Risk in Its Revised GLs for Prevention of AD
August 8, 2011
- Recommendation for Approval Withheld for Avastin for Breast Cancer
August 8, 2011
- SUEVEY
August 8, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…